|
NPPA fixes retail price of 20 new drugs
|
|
Gireesh Babu, New Delhi
October 16 , 2024
|
|
|
The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail price of 20 new drugs under the provisions of the Drugs Prices Control Order (DPCO), 2013 in its latest meeting.
The drugs for which the retail prices fix include two formulations of bisoprolol and amlodipine tablet marketed by Abbott Healthcare, gentamicin and dexamethasone eye drops and another formulation of levosalbutamol and ipratropium bromide respules from Mankind Prime Labs, and abacavir, dolutegravir and lamivudine combination from Aurobindo Pharma Ltd.
Retail price for cefuroxime axetil tablet from Dr Reddy's Laboratories, L-carnitine mecobalamin and folic acid tablet from Cadila Pharmaceuticals, sitagliptin, metformin hydrochloride and glimepiride tablet formulations from Unison Pharmaceuticals and Medley Pharmaceuticals, dapagliflozin, sitagliptin and metformin extended release tablet formulations from Primus Remedies, were also fixed during the meeting held on October 8, 2024.
The meeting also discussed the matters related to price fixation as per Pharmaceuticals Purchase Policy (PPP) for products of Pharma Central Public Sector Enterprises and their subsidiaries, said NPPA.
According to information from the Central Government, the Union Cabinet has in November, 2019, extended the PPP for pharmaceutical Central Public Sector Undertakings (CPSUs) till their closure/strategic disinvestment.
The extension of the policy was expected to help the pharma CPUs in optimum utilisation of their existing facilities, enable them to generate revenues to pay salaries to their employees, help them in keeping the costly, sophisticated machinery in running condition resulting in higher return at the time of disposal in case of CPSUs under closure and better valuation in case of CPSUs under disinvestment.
The PPP was approved by the Cabinet on October 30, 2013 for a period of five years in respect of 103 medicines manufactured by pharma CPSUs and their subsidiaries. The policy is applicable to purchases by Central/ State Government departments and their Public Sector Undertakings etc, according to the Prime Minister's Office.
The pricing of the products is done by National Pharmaceutical Pricing Authority. The procuring entity can purchase from pharma CPSUs and their subsidiaries subject to their meeting Good Manufacturing Practices (GMP) norms as per Schedule ‘M’ of the Drugs & Cosmetic Rules. The term of the policy expired on December 9, 2018.
Meanwhile, the government also decided in December, 2016, to close Indian Drugs and Pharmaceutical Ltd (IDPL) and Rajasthan Drugs and Pharmaceuticals Ltd (RDPL) and strategically sell Hindustan Antibiotics Ltd (HAL) and Bengal Chemicals and Pharmaceuticals Ltd (BCPL), after meeting their liabilities from proceeds of sale of their surplus land to government agencies. Later, the Centre also decided in November, 2017 for disinvestment of 100 per cent of its equity in another pharma CPSU, Karnataka Antibiotics and Pharmaceuticals Ltd.
It was in this context, the Cabinet in 2019, proposed to extend the policy till final closure or sale of these pharma CPSUs.
|
|
|
|
|
|
|
|
TOPICS
|
That foods might provide therapeutic benefits is clearly not a new concept. ...
|
|
|
|
|